Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target
Bristol Myers to buy RayzeBio for about $4.1B
Bristol Myers strikes $4.1 bln RayzeBio deal for targeted cancer therapies
Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion
Bristol Myers to buy RayzeBio for more than 100% premium, in a deal valued at $4.1 billion
RayzeBio stock opens with a big gain, to push valuation up to $1.4 billion
RayzeBio valued at nearly $1 billion as upsized IPO prices at top of expected range
RayzeBio sets IPO terms, to be valued at up to $1 billion